Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALM: Precision therapy versus standard therapy in AML and MDS in elderly
2023-509092-16-00Phase 2Completed
- Sponsor
- Akershus University Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of decitabine, azacitidine, venetoclax, sorafenib, etoposide and 4 more in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 1 more (2 arms), sponsored by Akershus University Hospital. Primary endpoint: Cost-effectiveness of precision therapy. Started Oct 2024; status: completed.
02
Drugs
decitabineazacitidinevenetoclaxsorafenibetoposide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on 2023-509092-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509092-16-00.